top of page

ASTHMA

Pulm_01.png
Ola.gif

Our innovative solution

Lact AS: development of a recombinant live biotherapeutic
to treat severe asthma

 In the LactAs project, our consortium aims to engineer the first recombinant LBP designed to treat asthma patients who do not respond to current treatments by integrating several modes of action in a single live biotherapeutic strain:

 

▪ Promotion of tissue regeneration.

 

▪ Inhibition of Th2 response

 

▪ Degradation of excess DNA

 

▪ Modulation of microbiome dysbiosis

Public-Private Collaboration Project CPP2021-008552 (2022): 1,148,219€

Pulmobiotics_logo.png
IRB.png
biysc_crg_logo.jpg.png
bottom of page